1. Home
  2. BRW vs CCCC Comparison

BRW vs CCCC Comparison

Compare BRW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRW

Saba Capital Income & Opportunities Fund SBI

HOLD

Current Price

$7.02

Market Cap

308.8M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$1.92

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRW
CCCC
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.8M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BRW
CCCC
Price
$7.02
$1.92
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.25
AVG Volume (30 Days)
222.1K
1.9M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
15.59%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.15
$1.09
52 Week High
$8.30
$4.26

Technical Indicators

Market Signals
Indicator
BRW
CCCC
Relative Strength Index (RSI) 41.65 34.02
Support Level $6.92 $1.93
Resistance Level $7.02 $2.13
Average True Range (ATR) 0.07 0.13
MACD 0.00 -0.03
Stochastic Oscillator 39.56 2.53

Price Performance

Historical Comparison
BRW
CCCC

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: